William C. Hahn

TL;DR: A genome-scale shRNA viability screen in human cancer cell lines was used to systematically identify genes that are essential in the context of particular copy-number alterations (copy-number associated gene dependencies) and identify partial copy-loss of wild-type SF3B1 as a novel, non-driver cancer gene dependency.

TL;DR: A type II RAF inhibitor is identified that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers and may be an effective therapeutic for BRAF mutant pediatric astrocytomas.

TL;DR: Aberrant β-catenin signaling plays a key role in several cancer types, notably colon, liver, and breast cancer as mentioned in this paper, but approaches to modulate β-Catenin activity for therapeutic purposes have proven elusive to date.

TL;DR: A rapid and sensitive genotyping assay to detect somatic single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1) promoter can establish the diagnosis of low-cellularity tumors like glioma and could be adapted to the point-of-care diagnosis of other lesions similarly defined by highly recurrent somatic mutations.

TL;DR: Sp46 appears to be a novel extracellular glycoprotein, high- level constitutive expression of which is restricted to mesoderm- derived epithelial and endothelial cells, and is proposed for it the name "mesosecrin."